tiprankstipranks
Protagonist Therapeutics (PTGX)
NASDAQ:PTGX
US Market
PTGX
Protagonist Therapeutics
RESEARCH TOOLSreports

Protagonist Therapeutics (PTGX) Stock News & Sentiment

736 Followers
Icotyde’s Strong Approval Outlook and Protagonist’s Strengthening Royalties Underpin Buy Rating and $117 Target
Premium
Ratings
Icotyde’s Strong Approval Outlook and Protagonist’s Strengthening Royalties Underpin Buy Rating and $117 Target
23d ago
PTGX
Entera Bio Moves Toward Phase 3 With Oral Therapy That Could Transform Osteoporosis Treatment (NASDAQ: ENTX)
Premium
TipRanks Newswire
Entera Bio Moves Toward Phase 3 With Oral Therapy That Could Transform Osteoporosis Treatment (NASDAQ: ENTX)
1M ago
AZN
IBO
Regulatory Turbulence: FDA Disruptions and U.S. Government Shutdown Threaten Protagonist Therapeutics’ Development Timelines
Premium
Company Announcements
Regulatory Turbulence: FDA Disruptions and U.S. Government Shutdown Threaten Protagonist Therapeutics’ Development Timelines
1M ago
PTGX
Protagonist Therapeutics: Near-Term Cash Windfall and Strategic Partnerships Underpin Buy-Rated, Self-Funded Growth Story
Premium
Ratings
Protagonist Therapeutics: Near-Term Cash Windfall and Strategic Partnerships Underpin Buy-Rated, Self-Funded Growth Story
1M ago
PTGX
Protagonist Therapeutics: Late-Stage Pipeline Strength and Rusfertide Economics Drive Buy Rating and $100 Price Target
Premium
Ratings
Protagonist Therapeutics: Late-Stage Pipeline Strength and Rusfertide Economics Drive Buy Rating and $100 Price Target
1M ago
PTGX
Protagonist Therapeutics: Advancing Multi-Asset Inflammation and Obesity Pipeline with Strong Cash Runway Supports Buy Rating
Premium
Ratings
Protagonist Therapeutics: Advancing Multi-Asset Inflammation and Obesity Pipeline with Strong Cash Runway Supports Buy Rating
3M ago
PTGX
Protagonist Therapeutics Highlights Diversified Pipeline and Partnerships
Premium
Company Announcements
Protagonist Therapeutics Highlights Diversified Pipeline and Partnerships
3M ago
8K
PTGX
More PTGX News >

PTGX News on the Web

Protagonist Therapeutics price target raised to $116 from $104 at Clear Street
TipRanks News
Bullish
Protagonist Therapeutics Executives Quietly Cash In on Major Insider Stock Sales
TipRanks News
Bullish
Can New Drugs Drive J&J's Innovative Medicine Despite Stelara LOE?
Zacks
Bullish
J&J's Pipeline Surge Sets Up Stronger Growth From New Drugs in 2026
Zacks
Bullish
Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX), Olema Pharmaceuticals (OLMA) and Medios AG (OtherMEDOF)
TipRanks News
Neutral
Top Executive Makes Major Move With Protagonist Therapeutics Stock
TipRanks News
Neutral
J&J Stock Trading Above 200- & 50-Day SMA for 8 Months: Time to Buy?
Zacks
Bullish
Analysts Are Bullish on Top Healthcare Stocks: Protagonist Therapeutics (PTGX), MDxHealth (MDXH)
TipRanks News
Bullish

News Score - Last 7 Days

Neutral
PTGX
Sector Average
Media Buzz
This Week1 articles
Weekly Average7.75 articles
News Sentiment
This Week100%
Sector Average68%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is PTGX’s Media Buzz Sentiment?
1 articles about PTGX were published this week. In an average week, 7.75 articles are published.
    What is PTGX’s weekly average amount of articles?
    In an average week, 7.75 articles about PTGX are published.
      What is PTGX’s News Sentiment?
      100% of articles about PTGX were positive this week, compared to its sector average of 68%.
        Healthcare Stocks that are Trending in the News
        AORTArtivion
        NBIXNeurocrine
        STAAStaar Surgical
        SLPSimulations Plus
        OWLTOwlet
        Showing the stocks with the most bullish news sentiment over the past week